Ohad Karnieli | Chief Executive Officer and Co Founder
Atvio Biotechnology

Ohad Karnieli, Chief Executive Officer and Co Founder, Atvio Biotechnology

Dr Karnieli is the founder and CEO of ATvio Biotech, a lead cell & gene therapy CDMO located in Israel focuses on process development and virus manufacturing. Dr Karnieli earned his PhD from the Tel Aviv university and his MBA from the Haifa university. Dr Karnieli serves as the chair of the process and product development committee of the International Society for Cellular Therapies (ISCT). Additionally, Dr Karnieli runs his own consultancy services (Karnieli Ltd) for cell therapy process development, automation and cGMP manufacturing with innovative and proprietary cell therapy technologies.  Prior to founding Atvio, Dr Karnieli was the vice president of Technology and Manufacturing at Pluristem Therapeutics

Appearances:



Advanced Therapies and Regenerative Medicine Day 2 - Thursday 17th May 2018 @ 11:40

Panel discussion: Assessment of health technology and market access globally, challenges and pricing

  • How are the logistical challenges for cell and gene therapies going to work in the years ahead?
  • Affordability and sustainability. How are health authorities going to pay?
  • Process of health technology assessment
  • ROI considerations: what makes this product profitable?

back to speakers

 

TO SPONSOR / EXHIBIT

Erica Baeta
+44 (0)207 092 1152
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson
t/ +44 (0)207 092 1150
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor
+44 (0)207 092 1257
issa.mauthoor@terrapinn.com